136 related articles for article (PubMed ID: 9479878)
1. Usefulness of FDG-PET in diagnosing primary lymphoma of the liver.
Bangerter M; Moog F; Griesshammer M; Merkle E; Hafner M; Ellenrieder V; Reske SN; Heimpel H
Int J Hematol; 1997 Dec; 66(4):517-20. PubMed ID: 9479878
[TBL] [Abstract][Full Text] [Related]
2. F-18 FDG positron emission tomography in primary breast non-Hodgkin's lymphoma.
Bakheet SM; Bakheet R; Ezzat A; Tulbah A; Durakovic A; Hussain S
Clin Nucl Med; 2001 Apr; 26(4):299-301. PubMed ID: 11290887
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?
Spaepen K; Stroobants S; Dupont P; Van Steenweghen S; Thomas J; Vandenberghe P; Vanuytsel L; Bormans G; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
J Clin Oncol; 2001 Jan; 19(2):414-9. PubMed ID: 11208833
[TBL] [Abstract][Full Text] [Related]
4. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Torizuka T; Nakamura F; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Kobayashi M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
6. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma.
Hoffmann M; Vogelsang H; Kletter K; Zettinig G; Chott A; Raderer M
Gut; 2003 Mar; 52(3):347-51. PubMed ID: 12584214
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL).
Najjar F; Hustinx R; Jerusalem G; Fillet G; Rigo P
Cancer Biother Radiopharm; 2001 Aug; 16(4):297-304. PubMed ID: 11603000
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
Spaepen K; Mortelmans L
Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
[TBL] [Abstract][Full Text] [Related]
10. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
[TBL] [Abstract][Full Text] [Related]
11. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
[TBL] [Abstract][Full Text] [Related]
12. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
14. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
15. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
16. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
Chiusolo P; Sica S; Leone G
Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
[TBL] [Abstract][Full Text] [Related]
17. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma.
Jerusalem G; Warland V; Najjar F; Paulus P; Fassotte MF; Fillet G; Rigo P
Nucl Med Commun; 1999 Jan; 20(1):13-20. PubMed ID: 9949408
[TBL] [Abstract][Full Text] [Related]
18. Stage IE non-Hodgkin's thyroid lymphoma on (18)F-FDG-PET/CT.
Mehta A; Muthukrishnan A
Hell J Nucl Med; 2011; 14(2):186-7. PubMed ID: 21761029
[No Abstract] [Full Text] [Related]
19. Evaluation of decreased uptake of 18F-fluorodeoxyglucose in the cerebral cortex of patients with intracranial non-Hodgkin's lymphoma lesions through PET/CT.
Zhang Q; Tian T; Wang L; Qiu H; Li D
Biomed Pharmacother; 2016 Dec; 84():1331-1336. PubMed ID: 27810790
[TBL] [Abstract][Full Text] [Related]
20. Extranodal malignant lymphoma: detection with FDG PET versus CT.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Merkle E; Frickhofen N; Reske SN
Radiology; 1998 Feb; 206(2):475-81. PubMed ID: 9457202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
